BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy [Pediatric Oncology]

Conclusion
In children with LCH, BRAFV600E mutation was associated with high-risk features, permanent injury, and poor short-term response to chemotherapy. Further population-based studies should be undertaken to confirm our observations and to assess the impact of BRAF inhibitors for this subgroup of patients who may benefit from targeted therapy.

Source: Journal of Clinical Oncology - August 23, 2016 Category: Cancer & Oncology Authors: Heritier, Emile, Barkaoui, Thomas, Fraitag, Boudjemaa, Renaud, Moreau, Peuchmaur, Chassagne-Clement, Dijoud, Rigau, Moshous, Lambilliotte, Mazingue, Kebaili, Miron, Jeziorski, Plat, Aladjidi, Ferster, Pacquement, Galambrun, Brugieres, Leverger, Mansuy, Pa Tags: Histiocytic Disorders, Oncogenes Pediatric Oncology Source Type: research